FDA actions in brief
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Abatacept (Orencia, Bristol-Myers Squibb) was approved to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
FDA approved divalproex extended-release tablets (Depakote ER, Abbott) for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
